Collaboration, License, and Other Agreements - Summary (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenues:
Revenue	$ 97,231	$ 104,031	$ 194,760	$ 192,876
Collaborative arrangements revenue
Revenues:
Revenue	97,231	103,386	194,760	192,051
Collaborative arrangement, other agreements
Revenues:
Revenue	409	408	889	812
Sale of active pharmaceutical ingredient
Revenues:
Revenue		645		825
AbbVie | Sale of active pharmaceutical ingredient
Revenues:
Revenue		69		228
AbbVie | North America | Collaborative arrangements revenue
Revenues:
Revenue	95,061	101,038	189,962	187,537
AbbVie | North America | Collaborative arrangement, collaboration and license agreements
Revenues:
Revenue	95,061	101,038	189,962	187,537
AbbVie | Europe and Other | Collaborative arrangement, collaboration and license agreements
Revenues:
Revenue	528	574	1,138	1,174
AstraZeneca | Collaborative arrangement, collaboration and license agreements
Revenues:
Revenue	148	200	340	410
AstraZeneca | Sale of active pharmaceutical ingredient
Revenues:
Revenue		576		597
Astellas Pharma Inc. | Collaborative arrangement, collaboration and license agreements
Revenues:
Revenue	500	570	1,023	1,066
Alnylam | Collaborative arrangement, co-promotion agreements
Revenues:
Revenue	$ 585	$ 596	$ 1,408	$ 1,052